Table 2 Patient characteristics
Total number of patients | 69 |
Age (years) | |
 Median (range) | 66 (40–88) |
Gender | |
 Male | 26 (38%) |
 Female | 43 (62%) |
ECOG performance status (at the start of EGFR-TKIa) | |
 0 | 34 (49%) |
 1 | 17 (25%) |
 2 | 17 (25%) |
 ≥ 3 | 1 (1%) |
Pathologic diagnosis | |
 Adenocarcinoma | 68 (99%) |
 Pleomorphic carcinoma | 1 (1%) |
Stagea (at initial diagnosis) | |
 I | 4 (6%) |
 II | 4 (6%) |
 III | 9 (13%) |
 IV | 52 (75%) |
EGFR mutation | |
 Exon 19 deletion | 33 (48%) |
 Exon 21 L858R | 31 (45%) |
 Other | 5 (7%) |
EGFR-TKI treatment | |
 Gefitinib | 57 (83%) |
 Erlotinib | 12 (17%) |
Line of EGFR-TKI therapy | |
 First line | 37 (53%) |
 Second line | 19 (29%) |
 Third line or greater | 13 (18%) |